Managing Early HER2+ mBC: Patient-Centered Approaches and Evolving Treatment Strategies

Opinion
Video

Experts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.

Video content above is prompted by the following:

  • What have been your care strategies for brain metastasis that are beneficial for the patients and their families.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
5 experts in this video
Image of a man in scrubs with short hair and glasses
Photo of a woman with brown hair and bangs, surrounded by a blue border
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Related Content
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article
Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Simple line illustration of breast tissue on a yellow background

PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer

Roman Fabbricatore
February 10th 2025
Article

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

Simple line illustration on a yellow background of a breast with the tissue illustrated

T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval

Chris Ryan
February 5th 2025
Article

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

Oncology Drugs Approved by the FDA in January 2025

Darlene Dobkowski, MA
February 3rd 2025
Article

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

light blue background with a white outline indicating breast tissue

Inavolisib Combo Improves Survival in Advanced Breast Cancer

Courtney Flaherty
February 1st 2025
Article

Inavolisib in combination with palbociclib and fulvestrant improved overall survival compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.